 - Patient must be refractory to or intolerant of prior therapy with a fluoropyrimidine, oxaliplatin, irinotecan, andor anti-angiogenic therapy. Patients with K-RAS wild type tumors must have received an epidermal growth factor receptor EGFR inhibitor such as cetuximab or panitumumab. 